Bryan Johnson· Author
Canagliflozin, an SGLT-2 inhibitor approved for the treatment of type-2 diabetes, produced significant lifespan increase in heterozygous mice.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Canagliflozin, an SGLT-2 inhibitor approved for the treatment of type-2 diabetes, produced significant lifespan increase in heterozygous mice.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Notably the effect was exclusive to male mice.
canaga flows and works at least in males quite well in middle-aged mice which is unpublished